Goldstein J - Search Results

1

Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study.

Alvarado D, Maurer M, Gedrich R, Seibel SB, Murphy MB, Crew L, Goldstein J, Crocker A, Vitale LA, Morani PA, Thomas LJ, Hawthorne TR, Keler T, Young D, Crowley E, Kankam M, Heath-Chiozzi M. Alvarado D, et al. Among authors: goldstein j. Allergy. 2022 Aug;77(8):2393-2403. doi: 10.1111/all.15262. Epub 2022 Mar 3. Allergy. 2022. PMID: 35184297 Free PMC article. Clinical Trial.

2

Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.

Vitale LA, Thomas LJ, He LZ, O'Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, Baronas AR, Gergel LE, Boyer JM, Sisson C, Goldstein J, Marsh HC Jr, Keler T. Vitale LA, et al. Among authors: goldstein j. Cancer Immunol Immunother. 2019 Feb;68(2):233-245. doi: 10.1007/s00262-018-2267-0. Epub 2018 Oct 31. Cancer Immunol Immunother. 2019. PMID: 30382327

3

Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.

Vitale LA, He LZ, Thomas LJ, Wasiuk A, O'Neill T, Widger J, Crocker A, Mills-Chen L, Forsberg E, Weidlick J, Patterson C, Hammond RA, Boyer J, Sisson C, Alvarado D, Goldstein J, Marsh HC Jr, Keler T. Vitale LA, et al. Among authors: goldstein j. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137. doi: 10.1007/s00262-020-02610-y. Epub 2020 May 25. Cancer Immunol Immunother. 2020. PMID: 32451681 Free PMC article.

4

CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy.

Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J, Crocker A, Thomas LJ, Goldstein J, Marsh HC, Keler T, He LZ. Wasiuk A, et al. Among authors: goldstein j. J Immunol. 2017 Dec 15;199(12):4110-4123. doi: 10.4049/jimmunol.1700606. Epub 2017 Nov 6. J Immunol. 2017. PMID: 29109120 Free PMC article.

5

Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.

Vitale L, Blanset D, Lowy I, O'Neill T, Goldstein J, Little SF, Andrews GP, Dorough G, Taylor RK, Keler T. Vitale L, et al. Among authors: goldstein j. Infect Immun. 2006 Oct;74(10):5840-7. doi: 10.1128/IAI.00712-06. Infect Immun. 2006. PMID: 16988263 Free PMC article.

6

Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.

Bevaart L, Goldstein J, Vitale L, Russoniello C, Treml J, Zhang J, Graziano RF, Leusen JH, van de Winkel JG, Keler T. Bevaart L, et al. Among authors: goldstein j. Br J Haematol. 2006 Feb;132(3):317-25. doi: 10.1111/j.1365-2141.2005.05884.x. Br J Haematol. 2006. PMID: 16409296 Free article.

7

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.

Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, Keler T, Endres MJ. Ramakrishna V, et al. Among authors: goldstein j. J Immunol. 2004 Mar 1;172(5):2845-52. doi: 10.4049/jimmunol.172.5.2845. J Immunol. 2004. PMID: 14978085

8

A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta.

He LZ, Ramakrishna V, Connolly JE, Wang XT, Smith PA, Jones CL, Valkova-Valchanova M, Arunakumari A, Treml JF, Goldstein J, Wallace PK, Keler T, Endres MJ. He LZ, et al. Among authors: goldstein j. Clin Cancer Res. 2004 Mar 15;10(6):1920-7. doi: 10.1158/1078-0432.ccr-03-0264. Clin Cancer Res. 2004. PMID: 15041707

9

Targeting tumor cell destruction with CD64-directed bispecific fusion proteins.

Graziano RF, Goldstein J, Sundarapandiyan K, Somasundaram C, Keler T, Deo YM. Graziano RF, et al. Among authors: goldstein j. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):124-7. doi: 10.1007/s002620050413. Cancer Immunol Immunother. 1997. PMID: 9435854 No abstract available.

10

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.

Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, Houtkamp M, Halk E, Goldstein J, Schuurman J, van Dijk MA, van de Winkel JG, Parren PW. Bleeker WK, et al. Among authors: goldstein j. J Immunol. 2004 Oct 1;173(7):4699-707. doi: 10.4049/jimmunol.173.7.4699. J Immunol. 2004. PMID: 15383606

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,181 results

Search Page